Ombitasvir / Paritaprevir / Ritonavir Dosage
Applies to the following strength(s): 12.5 mg-75 mg-50 mg
The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist.
Usual Adult Dose for:
Additional dosage information:
Usual Adult Dose for Chronic Hepatitis C
2 tablets orally once a day (in the morning)
Recommended Regimen and Duration of Therapy:
-Genotype 4, without cirrhosis: Ombitasvir/paritaprevir/ritonavir and ribavirin for 12 weeks
-Before starting this drug, baseline hepatic laboratory and clinical parameters should be assessed.
-The manufacturer product information should be consulted for ribavirin dosing recommendations, including dose adjustments.
-Use of this drug without ribavirin may be considered for therapy-naive patients who cannot take or tolerate ribavirin.
Use: In combination with ribavirin, for the treatment of patients with genotype 4 chronic HCV infection without cirrhosis
Renal Dose Adjustments
Mild, moderate, or severe renal dysfunction: No adjustment recommended.
-If required, the manufacturer product information for ribavirin should be consulted regarding use in patients with renal dysfunction.
Liver Dose Adjustments
Mild liver dysfunction (Child-Pugh A): No adjustment recommended.
Moderate to severe liver dysfunction (Child-Pugh B and C): Contraindicated
Safety and efficacy have not been established in patients younger than 18 years.
Consult WARNINGS section for additional precautions.
Data not available
-Administer with a meal, without regard to fat or calorie content.
-Consult the manufacturer product information regarding missed doses.
-Store at or below 30C (86F).
-Each fixed-dose combination tablet contains ombitasvir 12.5 mg, paritaprevir 75 mg, and ritonavir 50 mg.
-The manufacturer product information for ribavirin should be consulted for additional information.
-Hepatic: Baseline hepatic laboratory and clinical parameters (before starting therapy); hepatic laboratory tests (at baseline, during first 4 weeks of therapy, then as clinically indicated); ALT (if increases above baseline)
-Read the US FDA-approved patient information (Medication Guide) for this drug and review the Medication Guide for ribavirin, if applicable.
-Watch for signs of liver inflammation/failure (e.g., early signs: fatigue, weakness, lack of appetite, nausea and vomiting; later signs: jaundice, onset of confusion, abdominal swelling, discolored feces); consult healthcare provider immediately if these symptoms develop.
More about ombitasvir/paritaprevir/ritonavir
- Side Effects
- During Pregnancy
- Dosage Information
- Drug Interactions
- Support Group
- En Español
- 0 Reviews – Add your own review/rating
- Drug class: antiviral combinations
Other brands: Technivie
- Ombitasvir, Paritaprevir, and Ritonavir (AHFS Monograph)
- Ombitasvir, Paritaprevir, and Ritonavir (Wolters Kluwer)